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Joint hypermobility is a common, mostly benign, finding in the general population. In a subset of individuals, however, it causes a
range of clinical problems, mainly affecting the musculoskeletal system. Joint hypermobility often appears as a familial trait and is
shared by several heritable connective tissue disorders, including the hypermobility subtype of the Ehlers-Danlos syndrome (EDS-
HT) or benign joint hypermobility syndrome (BJHS). These hereditary conditions provide unique models for the study of the
genetic basis of joint hypermobility. Nevertheless, these studies are largely hampered by the great variability in clinical presentation
and the often vague mode of inheritance in many families. Here, we performed a genome-wide linkage scan in a unique three-
generation family with an autosomal dominant EDS-HT phenotype and identified a linkage interval on chromosome 8p22-8p21.1,
with a maximum two-point LOD score of 4.73. Subsequent whole exome sequencing revealed the presence of a unique missense
variant in the LZTS1 gene, located within the candidate region. Subsequent analysis of 230 EDS-HT/BJHS patients resulted in the
identification of three additional rare variants.This is the first reported genome-wide linkage analysis in an EDS-HT family, thereby
providing an opportunity to identify a new disease gene for this condition.
1. Introduction
Joint hypermobility is a common finding in the general popu-
lationwith epidemiologic studies showing its presence in over
10% of Caucasians. It is more prevalent among Asians and
Africans than Caucasians, with women affected more often
than men, and it is usually maximal at birth, decreasing with
age [1]. Joint hypermobility has a strong genetic component,
with female twin studies showing that at least 70% of the
variance in phenotype is attributed to genetic factors [2].
Most people do not develop any problems from their loose
joints andmight even benefit from it (e.g.,musicians, dancers,
and gymnasts). However, in a subset of individuals, joint
hypermobility gives rise to a range of clinical problems that
mainly affect the musculoskeletal system. It can be found as
a part of some well-defined heritable connective tissue dis-
orders, including the Ehlers-Danlos syndrome (EDS). EDS
comprises a clinically and genetically heterogeneous group
of heritable connective tissue disorders that are currently
classified according to the Villefranche nosology into six
subtypes, based on clinical symptoms, inheritance pattern,
and the nature of the underlying biochemical and molecular
defect(s) [3]. The major clinical manifestations, including
joint hypermobility, skin hyperextensibility, and generalized
connective tissue fragility, are present to varying degrees in
each EDS subtype. In some of these subtypes, mutations
have been identified in genes encoding one of the fibrillar
collagen proteins (types I, III, and V collagen) or coding
for enzymes involved in the biosynthesis of those proteins
(ADAMTS2 andPLOD1).Themost prominent clinical feature
observed in the hypermobility subtype of EDS (EDS-HT,
former EDS type III) is generalized joint hypermobility with
recurrent dislocations and subluxations, in addition to mild
skin hyperextensibility and fragility. The joint hypermobility
leads to significant joint instability, chronic debilitating pain,
and loss of muscle strength, which ultimately results in
important physical handicap and often causes great psy-
chological distress. Although EDS-HT is one of the most
prevalent EDS subtypes, it remains a challenging condition,
at both the clinical and molecular level. There is currently
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no clear consensus regarding the exact clinical definition
and nosologic delineation of EDS-HT. Although considered
one and the same by many authorities, there is still debate
whether EDS-HT and benign joint hypermobility syndrome
(BJHS), which show important phenotypic overlap, represent
the same disorder [4]. Moreover, the molecular basis of these
conditions remains at present poorly explored. Amajor draw-
back for genetic studies is the variable phenotypic expression
and reduced penetrancewithin and between families,making
it often difficult to ascertain whether an individual is affected
or not.
Families in which the EDS-HT or BJHS phenotype is
transmitted in a clear autosomal dominant fashion provide
unique genetic models for the study of genes and molecular
pathways that are involved in the pathogenesis of joint hyper-
mobility. However, only a limited number of clinically well-
defined large families with EDS-HT or BJHS are available
for informative genetic linkage studies. In the past, sporadic
defects have been identified in the genes encoding fibrillar
types I, III, and V collagen, but in the large majority of
EDS-HT patients, molecular studies have not revealed causal
defects in any of these genes. Ultrastructural studies in
patients with EDS-HT have revealed abnormalities in both
morphology and diameter of the collagen fibrils, suggesting
that impaired collagen fibrillogenesis plays a central role in
its pathogenesis [5]. Tenascin-X (TNXB) haploinsufficiency
was reported in a small subset (5–10%) of patients with
EDS-HT and BJHS [6, 7]. This glycoprotein is involved
in the regulation of collagen fibrillogenesis. More recent
findings point to a role for other genes in the pathogenesis of
rare EDS(-like) conditions, including genes encoding a zinc
transporter (SLC39A13) [8, 9], a peptidyl-prolyl cis-trans iso-
merase (FKBP14) [10], and genes involved in the biosynthesis
of glycosaminoglycans (B4GALT7, B3GALT6, CHST14, and
DSE) [11–13].These observations demonstrate that other non-
collagenous molecules involved in the modification, folding,
or extracellular assembly of collagens could be causally linked
to the pathogenesis of EDS and joint hypermobility.
We present the identification of a new genetic locus for
EDS-HT in a large three-generation Belgian family through
genome-wide linkage analysis. In addition to sequencing a
number of interesting positional candidate genes, we applied
whole exome sequencing for two affected individuals in an
attempt to unravel the underlying genetic cause within this
candidate locus.
2. Materials and Methods
2.1. Patients. We examined a large three-generation family
from Belgian descent with EDS-HT. Affected family mem-
bers presented generalized joint hypermobility with related
musculoskeletal problems, in association with a mild dermal
phenotype, including soft skin, mild atrophic scarring, and
easy bruising. Thirty-four family members were examined
after full informed consent was obtained in accordance
with requirements of the Ethics Committee of the Ghent
University Hospital. Clinical history was taken from all
individuals and clinical examination was performed at two
different time points (time 0 and after 24 months) by the
corresponding author. In addition, another clinical geneticist
examined all individuals independently. Individuals were
classified as being “affected” if they fulfilled the Villefranche
criteria for EDS-HT [3] and the revised Brighton criteria
for BJHS [4] and as “unaffected” if they did not fulfill these
criteria. Individuals presenting with amilder joint phenotype
but with cutaneous manifestations compatible with EDS-HT
were classified as “unknown” (Table 1).
Blood and/or skin biopsy specimens were obtained and
RNA and genomic DNA (gDNA) were isolated. Total RNA
was isolated from cultured skin fibroblasts by Trizol and
treated with RNase-free DNase (Life Technologies Europe,
Ghent, Belgium). For the conversion to cDNA, Moloney
murine leukemia virus reverse transcriptase was used in
combination with random hexanucleotide primers (Invitro-
gen, Life Technologies Europe). gDNA was isolated from
fibroblast cultures by the Easy-DNA kit (Invitrogen) or
extracted fromblood samples using theQiaquick kit (Qiagen,
Hilden, Germany).
2.2. Cell Culture and Biochemical Analysis of Collagen
Molecules. Fibroblast cultures were established from a skin
biopsy from the proband (II.5) and an affected sister (II.6). At
confluency, cells were labelled with 14C-proline as described
earlier [14]. After separation, the gels were processed for
fluorography, dried, and exposed to an X-ray film.
2.3. Candidate Genes. As an initial step towards defining
the genetic basis of EDS-HT in this family, linkage to a
number of candidate genes, including the genes encoding
types I, III, and V collagen and tenascin-X (TNXB), was
tested by use of markers within and surrounding these
genes (Supplementary Table 1 in Supplementary Material
available online at http://dx.doi.org/10.1155/2015/828970). For
the linkage study to these genes, a series of 14 individuals,
independently assessed as “affected” (I.2, II.3, II.4, II.5, II.6,
II.7, III.6, III.8, III.10, and III.14), “unaffected” (I.1, II.2,
and III.7), or “unknown” (II.9) by both investigators, were
selected (Figure 1, individuals with an asterisk).
2.4. Genome-Wide Linkage Analysis. A genome-wide linkage
scan was performed using gDNA from the same 14 indi-
viduals (Figure 1, individuals indicated with an asterisk). A
set of 400 highly polymorphic microsatellite markers (ABI
PRISM Linkage Mapping Set version 2, Applied Biosys-
tems, Foster City, CA, USA) with an average spacing of 10
centimorgans (cM) were analyzed on a capillary sequencer
(ABI3100, Applied Biosystems). The data were processed
using GeneMapper software (Applied Biosystems). The anal-
ysis was performed under the assumption that the condition
is inherited as an autosomal dominant trait with a penetrance
of 90% at all ages. A disease allele frequency of 0.01 (1/100)
and equal recombination fractions in males and females
were assumed. Two-point LOD scores were calculated with
SuperLink version 1.6.
After the initial assessment of a linked chromosomal
region in 14 individuals, gDNA of these individuals and
Disease Markers 3
Ta
bl
e
1:
Cl
in
ic
al
ch
ar
ac
te
ris
tic
so
fa
ffe
ct
ed
an
d
un
aff
ec
te
d
fa
m
ily
m
em
be
rs
.
A
ge
∗
(y
ea
rs
)
Be
ig
ht
on
sc
or
e(
/9
)
A
rt
hr
al
gi
a
(S
ub
)lu
xa
tio
n
Cu
ta
ne
ou
s
Te
nd
on
iti
s,
m
us
cle
cr
am
ps
O
th
er
St
at
us
CM
PS
>
4
jo
in
ts
CM
PS
1–
3
jo
in
ts
Ea
sy
br
ui
sin
g
So
ft
sk
in
Sk
in
hy
pe
re
xt
en
sib
ili
ty
At
ro
ph
ic
sc
ar
rin
g/
di
la
te
d
sc
ar
s
St
ria
e
I.2
75
5
+
H
ip
,T
M
J,
an
d
ste
rn
oc
la
vi
cu
la
r
jo
in
t
+
+
−
+
−
H
er
ni
au
m
bi
lic
al
is,
po
sto
pe
ra
tiv
e
ha
em
or
rh
ag
es
,a
nd
fr
ag
ili
ty
of
in
te
rn
al
or
ga
ns
A
II
.1
47
2
+
A
nk
le
s
−
−
−
+
+
−
U
II
.2
46
0
−
−
−
−
−
−
−
−
N
A
II
.3
45
6
+
+
+
−
−
+
+
O
ste
op
en
ia
,
ke
ra
to
co
nu
s,
an
d
m
us
cle
ru
pt
ur
es
A
II
.4
44
5
+
Fi
ng
er
s,
TM
J
+
+
+
+
+
+
D
isc
us
he
rn
ia
A
II
.5
43
9
+
G
en
er
al
iz
ed
+
+
−
+
+
+
A
II
.6
42
5
+
G
en
er
al
iz
ed
+
+
−
−
+
+
A
II
.7
36
3
+
Sh
ou
ld
er
s,
w
ris
ts,
an
d
pa
te
lla
+
+
+
+
+
+
A
II
.8
34
2
−
−
+/
−
−
−
+
−
U
II
.9
32
3
−
−
Sh
ou
ld
er
−
−
−
++
+
−
U
II
I.1
24
0
−
−
−
−
−
−
−
−
N
A
II
I.2
19
0
−
−
−
−
−
−
−
−
N
A
II
I.3
19
0
−
−
−
−
−
−
−
−
N
A
II
I.4
17
2
−
+
Pa
te
lla
+
−
−
−
−
−
U
II
I.5
15
2
−
−
−
−
−
−
−
−
N
A
II
I.6
14
7
−
Fi
ng
er
s,
an
kl
es
+
+
+
+
−
−
A
II
I.7
10
2
−
−
−
−
−
−
−
N
A
II
I.8
9
9
+
W
ris
t,
to
es
+
+
+
−
−
−
Tr
an
sp
ar
en
ts
ki
n
A
II
I.9
6
2
−
−
−
−
−
−
−
N
A
II
I.1
0
18
9
+
Fi
ng
er
s,
pa
te
lla
+
+
−
+
+
+
A
II
I.1
1
11
6
+
+
+
−
−
−
−
A
II
I.1
2
9
7
+
+
+
−
−
−
−
A
II
I.1
3
7
2
−
−
+/
−
+/
−
−
−
−
−
U
II
I.1
4
11
9
+
A
nk
le
s
+
+
+
−
−
−
A
II
I.1
5
11
2
−
−
−
−
−
−
−
N
A
II
I.1
6
7
6
−
−
−
+
−
+
−
−
A
CM
SP
:c
hr
on
ic
m
us
cu
lo
sk
ele
ta
lp
ai
n
fo
r>
3
m
on
th
s.
TM
J:
te
m
po
ro
m
an
di
bu
la
rj
oi
nt
.
A
:“
aff
ec
te
d,
”N
A
:“
no
ta
ffe
ct
ed
,”
an
d
U
:“
un
kn
ow
n.
”
∗
A
ge
at
la
st
cli
ni
ca
le
va
lu
at
io
n.
4 Disease Markers
I.1
II.1
I.2
II.2
III.1 III.2
II.3 II.4 II.5 II.6 II.7 II.8 II.9
III.3 III.4 III.5 III.6 III.7 III.8 III.9 III.10 III.11 III.12 III.13 III.14 III.15
?
? ?
?
D8S254
D8S261
D8S258
D8S1771
D8S1820
D8S254
D8S261
D8S258
D8S1771
D8S1820
D8S254
D8S261
D8S258
D8S1771
D8S1820
?
2
2
1
1
1
1
3
1
9
2
2
3
1
9
2
1
6
2
7
1
1
3
2
1
3
1
6
3
7
1
2
2
1
1
1
1
6
3
7
3
2
2
1
1
1
1
6
3
7
1
1
3
1
9
2
1
3
2
1
3
2
2
1
1
1
1
6
3
7
1
1
2
1
1
1
1
6
3
7
1
2
2
1
1
1
1
6
3
7
1
2
2
1
1
1
1
3
2
1
3
2
2
1
1
1
1
6
3
7
1
III.16
3
2
1
2
3
1
6
3
7
1
3
2
1
2
1
1
3
2
1
3
1
3
1
1
3
2
1
2
2
3
6
2
4
1
2
2
2
1
1
1
1
3
1
1
3
2
3
2
1
3
6
2
4
1
2
2
2
1
1
1
1
5
1
8
3
1
6
3
7
1
1
2
3
1
2
1
6
3
7
1
1
5
1
8
3
2
2
1
1
1
1
5
1
2
3
1
6
3
7
1
2
3
3
2
3
1
2
1
1
1
3
2
3
2
3
1
6
3
7
1
2
3
3
2
3
1
6
3
7
1
2
3
3
2
3
1
6
3
1
1
1
5
1
8
3
2
2
1
1
1
1
2
1
1
1
1
6
2
7
1
∗
∗∗∗
∗∗
∗
∗
∗ ∗
∗
∗∗
∗
Figure 1: Pedigree of the three-generation Belgian family. The genotypes of 5 markers within and surrounding the linked region on
chromosome 8 are depicted. The haplotype cosegregating with the EDS-HT phenotype is indicated with a black bar. An arrow indicates the
proband. Individuals included in the initial genome-wide linkage screen are indicated with an asterisk. Affected and unaffected individuals
are indicated with a black or white pictogram, respectively, whereas a grey pictogram with a question mark points to a patient for whom the
phenotype was not clear (unknown).
of 13 additional members was further analyzed with four
additionalmicrosatellitemarkers.Thesemarkerswere chosen
from the Marshfield and Ge´ne´thon genetic map for fine
genetic mapping and identifying the critical interval. Order
and distance between the markers were obtained from
the Ge´ne´thon genetic database: D8S254, 2.28 cM, D8S261,
4.51 cM, D8S258, 8.5 cM, D8S1771, 5.99 cM, and D8S1820.
Haplotypes were constructed, assuming theminimal number
of recombination, by tracing the segregation of alleles in the
family.
2.5.Molecular Analysis andGene Prioritization. Thepresence
of a causal mutation in one of the genes associated with
autosomal dominant forms of EDS was excluded by means of
mutation screening of COL1A1, COL1A2, COL3A1, COL5A1,
andCOL5A2 at cDNA level and ofTNXB at gDNA level in the
proband. Testing for the presence of aCOL5A1 nonfunctional
(null-)allele was performed in two affected individuals (II.5
and II.6). In analogy, testing for the presence of a TNXB
null-allele was performed in the same individuals, using
the following polymorphism: c.3482A>G (p.(His1161Arg)) in
exon 9.
For mutation analysis of the positional candidate genes
BMP1, LOXL2, CSGALNACT1, and SLC39A14, gDNA from
the proband, one additional affected family member, one
unaffected family member, and an unrelated normal con-
trol was PCR amplified using intronic primers designed to
amplify each exon and adjacent intron-exon boundaries. PCR
products were sequenced on the ABI PRISM 3100 automated
sequencer (Applied Biosystems). Detected single nucleotide
changes were considered a polymorphism either when they
were reported in the public databases (dbSNP137 and 1000
Genomes Project), or when they did not segregate with the
EDS-HT phenotype within the family.
Gene prioritization was performed with the web-based
algorithmsEndeavour [15], Suspects [16], G2D [17], GeneDis-
tiller [18], and ToppGene [19], using a training set of 14
EDS-associated genes (COL1A1, COL1A2, COL5A1, COL5A2,
COL3A1, TNXB, PLOD1, ADAMTS2, CHST14, B4GALT7,
SLC39A13, FKBP14, B3GALT6, and DSE).
2.6. Whole Exome Sequencing. Whole exome sequencing
(WES) was performed for two affected individuals (II.5 and
II.6) by Aros Applied Biotechnology AS (Aarhus, Denmark).
Exome capture was performed using the TruSeq Exome
Enrichment kit (Illumina, SanDiego, CA,USA) and sequenc-
ing was carried out on the IlluminaHiSeq 2000 platformwith
paired-end 100-bp reads.TheCLCGenomics workbench ver-
sion 6.0.4 (CLCBio, Aarhus, Denmark) software was used for
read mapping against the human genome reference sequence
(NCBI, GRCh37/hg19) followed by duplicate read removal
and coverage analysis for all regions enrichedwith the TruSeq
Exome Enrichment kit. Single nucleotide variants and small
insertions and deletions were called using the quality-based
variant calling and subsequently annotated prior to exporting
the resulting variant lists for filtering. The filter strategy
focused on retaining heterozygous variants (variant allele
frequency between 25% and 75%) shared between both sisters
located within the coding sequence or flanking intronic
regions (+/−20 bp) of the linkage region. Candidate variants
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Table 2: Two-point LOD scores for microsatellite markers on the 8p22-8p21.1 region for a given 𝜃.∗The identified candidate interval.
Marker 0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45
D8S254∗ 0.21 2.52 2.49 2.32 2.08 1.79 1.46 1.10 0.71 0.34
D8S261∗ 1.86 1.73 1.59 1.43 1.27 1.10 0.91 0.71 0.49 0.26
D8S258∗ 4.73 4.35 3.95 3.53 3.09 2.62 2.12 1.58 1.02 0.47
D8S1771∗ 2.04 3.36 3.26 3.01 2.69 2.32 1.89 1.43 0.92 0.42
D8S1820 −2.05 1.20 1.29 1.24 1.12 0.96 0.78 0.57 0.35 0.15
were evaluated using the mutation interpretation software
Alamut version 2.2.1 or Alamut HT version 1.1.5 (Interactive
Biosoftware, Rouen, France) and segregation analysis was
performed for selected variants.
2.7. Array Comparative Genomic Hybridization. In order to
evaluate copy number alterationswithin the identified region,
array comparative genomic hybridization (aCGH) was per-
formed on individuals II.2, II.9, II.11, II.15, III.2, III.6, III.10,
and III.14 (Figure 1) using a custom 8 × 60K oligonucleotide
array (Agilent Technologies, Santa Clara, CA, USA) covering
the exonic and intronic portions of the identified candidate
region (NCBI, GRCh37.p5/hg19) with a total of 52000 probes.
This assay was performed according to the manufacturer’s
instructions and the results were visualized and analysed
using arrayCGHbase [20].
2.8. Additional Families. Four additional families were ana-
lyzed for linkage to the candidate locus identified in the initial
family. These families were examined either by one of the
authors (Anne De Paepe or Fransiska Malfait) or by clinical
geneticists familiar with the disorder. All families were
considered to be affected by EDS-HT, based on the presence
of generalized joint hypermobility and related complications
of dislocations and chronic pain, in combination with a mild
dermal phenotype of soft and/or mildly hyperextensible skin,
mild atrophic scarring, and easy bruising.
3. Results
3.1. Clinical Data. The index patient (Figure 1, II.5) was
diagnosed with EDS-HT at young age. She presented severe
joint hypermobility since infancy with a life-long history of
recurrent subluxations and dislocations of many large and
small joints, for example, vertebral bodies, temporomandibu-
lar, acromioclavicular, sternoclavicular, glenohumeral, and
most other peripheral joints. Since adolescence, she suffered
from generalized pain and eventually became wheelchair
dependent for long distances at the age of 35 years. She
bruised easily after simple trauma and presented delayed
wound healing with formation of dilated scars.
After clinical evaluation, 13 individuals were scored
as “affected” and 9 as “unaffected.” Affected individuals
showed typical features of EDS-HT with joint hypermobility
(Beighton score > 5/9), chronic musculoskeletal pain, and,
especially in the adults, repetitive dislocations of one or more
joints. They all presented easy bruising, and most of them
had a soft skin with dilated scars. Many presented striae
atrophicae, especially over the thighs and the abdomen. None
of them had a marfanoid habitus. Five individuals with mild
joint hypermobility and some skin features were scored as
“unknown” (II.1, II.8, II.9, III.4, and III.13). A summary of
the clinical data is provided in Table 1.
3.2. Biochemical Analysis. SDS-PAGE of metabolically
labelled types I, III, and V (pro)collagen secreted by and
retained in fibroblasts of individual II.5 did not show qualita-
tive or quantitative abnormalities in electrophoretic mobility
(data not shown).
3.3. Exclusion of Candidate Genes. Segregation analysis
for candidate genes COL1A1, COL1A2, COL3A1, COL5A1,
COL5A2, and TNXB excluded linkage of the phenotype to
one of these genes (Supplementary Table 1). A null-allele test
forCOL5A1 andTNXB showed that both alleles of these genes
were transcribed.Molecular analysis of theCOL1A1,COL1A2,
COL3A1, COL5A1, and COL5A2 genes at cDNA level and
TNXB at gDNA level did not reveal a causal mutation.
Karyotype of the proband (II.5) was normal (46, XX).
3.4. Genomic Linkage Analysis. A systemic genome scan was
performed using gDNA of 14 family members in order to
identify a predisposition locus for EDS-HT in this family.
In the initial genome-wide linkage search, marker D8S258
generated the highest two-point LOD score of 2.5 at theta
(𝜃) = 0. No other markers exceeded the threshold LOD score
of 2.2, supposing suggestive linkage according to the criteria
of Lander and Kruglyak [21]. To confirm and refine this
possible predisposition locus, gDNA of these individuals and
13 additional family members was further analysed using
four additionalmicrosatellitemarkers. A haplotype ofmarker
alleles segregates with the disease in all affected individuals
(Figure 1). The candidate region was delineated by critical
recombination events between D8S254 and D8S261 at the
proximal end (telomeric) in individual II.5 and between
markers D8S258 and D8S1771 at the distal end (centromeric)
in individual III.12.This defined a candidate region of 8.8Mb,
flanked by markers D8S254 and D8S1771 encompassing the
cytogenic location 8p22-8p21.1. A maximum two-point LOD
score of 4.73 was obtained for D8S258 (Table 2). In order
to evaluate the contribution of this locus in other families,
the critical interval on chromosome 8 was examined in four
additional families with an EDS-HT phenotype. For none
of these families linkage of the 8p22-8p21.1 locus with the
disease phenotype could be observed (data not shown).
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Table 3: Ranking of the candidate genes according to different gene prioritization tools with functionally interesting candidates indicated in
bold.
Endeavour∗ Suspects G2D GeneDistiller ToppGene
1 BMP1 BMP1 CNOT7 BMP1 CSGALNACT1
2 LOXL2 LPL CSGALNACT1 CSGALNACT1 LPL
3 SLC39A14 CSGALNACT1 HR NPM2 BMP1
4 DOCK5 SLC39A14 ADAMDEC1 LOXL2 LOXL2
5 LPL ADAM7 GNRH1 LPL GNRH1
6 STC1 ADAM28 BMP1 STC1 FGF17
7 SORBS3 ADAMDEC1 NKX3-1 SLC39A14 SFTPC
8 NEFL LOXL2 STC1 GNRH1 FGF20
9 ADAM28 FGL1 SLC39A14 HR HR
10 ASAH1 PDLIM2 LPL GFRA2 STC1
11 CCAR2 LZTS1 NKX2-6 NAT1 DOK2
12 FGL1 FGF17 NAT1 TNFRSF10B DMTN
13 EGF17 KTCD9 NPM2 NKX3-1 PDLIM2
14 ENTPP4 SLC18A1 ENTPD4 SFTPC ATP6V1B2
15 PDGFRL PCM1 ADAM28 PDLIM2 NPM2
16 PFLIM2 DOCK5 ASAH1 TNFRSF10D FGL1
17 LZTS1 GFRA2 FGF17 SORBS3 NEFM
18 NAT1 SLC7A1 BIN3 POLR3D SLC39A14
19 VSP37A C8orf20 LOXL2 ASAH1 GFRA2
20 DOK2 STC1 ATP6V1B2 DOCK5 NEFL
∗CSGALNACT1 is not recognized by the Endeavour web tool.
3.5. Exclusion of Copy Number Alterations. Copy number
profiling was performed using custom aCGH, thereby focus-
ing on the gene-containing regions of the candidate interval.
This did not reveal deletions or duplications segregating with
the disease phenotype.
3.6. Selection andMolecular Screening of Positional Candidate
Genes. In silico analysis using NCBI MapViewer revealed
the presence of 102 known genes within the linkage interval
delineated by markers D8S254 and D8S1771 on chromosome
8p22-8p21.1. Of these genes, 20were indicated as pseudogene,
whereas the remaining genes include 69 protein-coding
genes, 8 uncharacterized (LOC) genes, three genes encoding
long noncoding RNAs, and two microRNAs (Supplementary
Figure S1). Within the candidate interval, no known genes
associated with EDS were present. The genes located in the
identified candidate region were prioritized using multiple
web-based prediction tools (Table 3) combined with a liter-
ature search. Four functionally interesting candidate genes,
including BMP1 (bone morphogenetic protein-1), LOXL2
(lysyl oxidase-like 2), CSGALNACT1 (chondroitin 𝛽1,4-N-
acetylgalactosaminyltransferase), and SLC39A14 (solute car-
rier family 39 (zinc transporter), member 14), were selected
for Sanger sequencing but no segregating sequence variant
that likely explained the connective tissue phenotype was
identified. Therefore, we expanded the search for the causal
mutation by applying whole exome sequencing.
3.7. Whole Exome Sequencing. WES performed for the
proband (II.5) and an affected sister (II.6) generated over
132 million reads for each, of which, respectively, 80.4%
and 81.2% mapped uniquely against the human reference
sequence. Approximately 93% of the enriched TruSeq target
regions were covered at least 10-fold in both patients and
about 90% of these regions were covered at least 20-fold. An
average read depth of 93.7x was achieved for the proband
(II.5) and 94.5x for her sister (II.6). Within the identified
candidate region, 85.5% of the targeted regions were covered
at least 20-fold in both patients whereas 3.4% and 3.6% of
these targets were partially (0.6% and 0.9%) or completely
(2.8% and 2.7%) uncovered for II.5 and II.6, respectively.
Single nucleotide variants and small insertions and dele-
tions were called using the CLCGenomics workbench. Given
the autosomal dominant inheritance pattern, only variants
that were heterozygous (with a variant allele frequency
between 25% and 75%) in both affected individuals and
located within the candidate region on chromosome 8 were
considered.This resulted in a total of 300 shared heterozygous
variants, which were narrowed down to 11 by selecting vari-
ants that result in nonsynonymous amino acid changes, the
introduction of a premature termination codon, frameshifts,
or (predicted) splice sites changes with an allele frequency
below 0.1 in dbSNP137. Comparison with 54 in-house exomes
showed that the majority of these variants occurred multiple
times in patients suffering from other inherited conditions,
thereby omitting these for further analysis. Combined with
the exclusion of variants that were predicted to be benign
by all four in silico prediction programs (SIFT, PolyPhen-
2, AlignGVGD, and MutationTaster), this filtering strategy
resulted in one uniquemissense variant p.(His211Gln) located
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Table 4: Overview of the LZTS1 variants identified in patients with EDS-HT or BJHS.
cDNA Protein SIFT PolyPhen-2 Align MutationGVGD Taster
c.633C>A p.(His211Gln) Tolerated Probably damaging C0 Disease-causing
c.49C>G p.(His17Asp) Tolerated Probably damaging C0 Disease-causing
c.1585C>T p.(Arg529Trp) Deleterious Probably damaging C0 Disease-causing
c.749C>A p.(Ser250∗) — — — —
within the LZTS1 gene, encoding leucine zipper, putative
tumor suppressor 1 (previously also reported as FEZ1). In
silico prediction tools indicated that the p.(His211Gln) substi-
tution was predicted to be tolerated by SIFT andAlignGVGD
but was considered damaging by both PolyPhen-2 and
MutationTaster. The affected amino acid residue is mod-
erately conserved. Sanger sequencing could confirm the
presence of this variant in all affected individuals whereas
unaffected family members lacked the variant. Subsequently,
we assessed the presence of LZTS1 sequence alterations in
230 probands diagnosed at or referred to our center with
EDS-HT or BJHS. This resulted in the identification of three
additional variants. The first variant, c.49C>G, p.(His17Asp)
was predicted to be damaging by both PolyPhen-2 and
MutationTaster and was reported a single time (1 in 13006
alleles, rs368057069) in theNHLBI exome sequencing project
exome variant server (http://evs.gs.washington.edu/EVS/).
The second variant, c.1585C>T, p.(Arg529Trp) was found in
two unrelated individuals and was predicted to be damaging
by SIFT, PolyPhen-2, and MutationTaster. The third variant,
c.749C>A, p.(Ser250∗) introduced a premature termination
codon in exon 2 and is predicted to result in nonsense
mediated mRNA decay (Table 4).
4. Discussion
Genetic studies in EDS-HT and BJHS are scarce because they
are hampered by several difficulties. First, the diagnosis in an
individual is not always obvious. Since joint hypermobility is
common in the general population, it is often difficult tomake
a clear distinction between those individuals at the upper
end of the normal “joint mobility spectrum” and those whose
increasedmobility reflects the presence of a connective tissue
disorder. For the vast majority of the EDS-HT patients, the
underlying molecular defect remains unknown. Therefore,
the diagnosis is entirely based on correct assessment of the
clinical phenotype as no pathognomonic, radiographic, bio-
chemical, ultrastructural, or other abnormalities are available
to confirm this.The joint hypermobilitymay decrease or even
completely disappear with increasing age.The extra-articular
symptoms such as the skin hyperextensibility, abnormal
scarring, or other signs of connective tissue fragility may be
very subtle. Second, the inheritance pattern in a family is
not always straightforward because of variable penetrance
and phenotypic expression. Joint hypermobility may be
influenced by specific environmental factors, such as hor-
monal status and degree of activity, and by different, yet to
be identified, genetic factors, such as polymorphic genetic
determinants in genes encoding proteins of the extracellular
matrix. Large families suitable for informative linkage studies
are therefore scarce.
This report presents the first successful linkage study
in a unique three-generation Belgian family in which EDS-
HT segregates with autosomal dominant inheritance pattern.
In order to make the clinical assessment in this family as
accurate as possible, the same physician (Fransiska Malfait)
was responsible for repeated clinical evaluation and history
taking. In addition to assessment of joint hypermobility
and musculoskeletal problems, a number of clinical signs,
indicative of generalized connective tissue fragility, were
registered.These were helpful for determining the phenotype
in individuals who were ambiguous on the joint phenotype
alone. After exclusion of a number of candidate genes, a sug-
gestive candidate locus was identified, which segregates with
the EDS-HT phenotype.The highest two-point LOD score of
4.73 was obtained for marker D8S258, highly suggestive for
linkage between the phenotype and this locus. A haplotype
of marker alleles segregated with the phenotype and critical
meiotic recombinants placed the EDS-HT predisposition
gene within an 8.8Mb region on chromosome 8p22-8p21.1.
Moreover, the absence of linkage for the identified locus
in several other EDS-HT families underscores the genetic
heterogeneity of the disorder.
Four of the protein-coding genes located within this
region were considered potentially promising candidate
genes for EDS-HT. BMP1 belongs to secreted metallopro-
teinases and was first described as a procollagen C-proteinase
for types I–III procollagen but is also responsible for the
cleavage of multiple other substrates (e.g., prolysyl oxidase,
prodecorin, and probiglycan). Biallelic defects in BMP1 were
recently described as the cause of a severe recessive variant
of the brittle bone disorder Osteogenesis imperfecta [22].
LOXL2 encodes lysyl oxidase-like 2, which belongs to the
family of lysyl oxidases and catalyses covalent cross-linking of
several fibrillar collagen types and elastin, whereas CSGALN-
ACT1 encodes a key enzyme for chain initiation and elonga-
tion of chondroitin/dermatan sulfate, one of the sulfated gly-
cosaminoglycan chains that are covalently attached to various
core proteins as proteoglycans. SLC39A14 encodes the zinc
transporter ZIP14, which is important for the intracellular Zn
status and as such is comparable to ZIP13, previously shown
to be mutated in the spondylocheirodysplastic form of EDS
[8, 9]. Investigation of these genes with Sanger sequencing
did not result in the identification of pathogenic alterations
segregating with the phenotype.
In a next step,WESwas performed for two affected sisters.
The applied variant filtering strategy narrowed the number
of shared heterozygous alterations down to a single missense
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variant in the LZTS1 gene which was found to segregate
with the disease phenotype. LZTS1 is a tumor suppressor
gene implicated in several human cancers. It is expressed
in different normal tissues (Supplementary Figure S2) and
was shown to be involved in cell cycle regulation through
prevention of Cdc25C degradation thereby regulating Cdk1
activity [23]. In addition to its role in cancer, LZTS1 was also
shown to be important during neuronal development [24].
LZTS1 belongs, together with LZTS2, LZTS3, and N4BP, to
the Fezzins, a family of proteins that share a leucine zipper Fez
domain [25]. LZTS1 itself was not linked to joint hyperlaxity,
but disruption of the ProSAP2 gene, encoding a protein
interacting with LZTS2 (LAPSER1), resulted in a syndrome
with mild intellectual disability and joint laxity [26, 27]. In an
attempt to verify LZTS1 as an EDS-HT predisposition gene,
it was screened in 230 unrelated probands with EDS-HT,
either evaluated at our connective tissue clinic or referred by
another clinical geneticist.This revealed the presence of three
additional LZTS1 variants. Nevertheless, the contribution of
these variants to the EDS-HTphenotype still remains unclear.
It has been previously reported that the LZTS1 gene and its
protein contain features resembling those of transcription
factors, which makes it tempting to speculate that LZTS1
could have a role in modulating gene transcription and
thereby affect the expression of genes encoding connective
tissue molecules [28]. At present, however, we have no con-
clusive evidence for an exact function of LZTS1 in connective
tissue biology and further studies are necessary to confirm
the pathogenic role of the identified sequence alterations.
If a functional link could be established, the phenotypic
discrepancy between patients with LZTS1 defects within the
same family could be attributed to incomplete penetrance
and/or variable expressivity. Our results already indicate
that LZTS1 mutations will likely account for only a small
proportion (around 2% as deduced from our results) of EDS-
HT patients.
It should also be noted that, as the majority of disease-
causing mutations reside within the protein-coding part of
the genome, our study focused on the exonic part of the can-
didate interval, thereby omitting the interrogation of impor-
tant noncoding regions, such as (deep) intronic regions,
promoter sequences, and other regulatory and conserved
sequences that reside within the candidate interval andwhich
can also contain disease-causing alterations. In addition,
the WES technology is also subjected to other limitations,
such as the lack of a (small) proportion of genes/exons on
the enrichment platform as well as the inefficient capturing
and/or incomplete sequencing of some regions. Collectively,
these issues can lead to false negative results and canmask the
true underlying cause.
Efforts towards the identification of genes underlying
joint hypermobility syndromes such as EDS-HT and BJHS
are important in order to gain better insights into the
clinical phenotypes, their natural history, and the underlying
pathogenic basis. Families with clear autosomal dominant
inheritance of EDS-HT probably represent rare forms of the
condition, but elucidation of the causal gene defect in these
families may allow identification of new genes and/or genetic
pathways that are involved in EDS and joint hypermobility.
This will improve early recognition and diagnosis of joint
hypermobility and lead to a more logical classification of
the hypermobility syndromes. For patients who are suffering
from these chronic and painful conditions, accurate clinical
diagnosis, confirmation of diagnosis by biochemical and/or
molecular testing, better understanding of the pathogenic
basis, and well-adjusted therapeutic follow-up by medical
and paramedical staff are important factors that will help
them cope with this condition and prevent feelings of
frustration and depression. Understanding the genetic basis
of joint hypermobility syndromes will moreover enhance
our understanding of normal connective tissue biology and
homeostasis and of mechanisms underlying EDS and joint
mobility.
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